Special Therapies · Vivecura Berlin

Ketamine-Assisted Therapy: Hope for Treatment-Resistant Mental Health Conditions

What the science actually says, and why the setting matters more than the substance.

Imagine there was a medication that worked in hours.

Not in six weeks. In hours.

A medication that, in clinical studies of people with treatment-resistant depression, achieves response rates of up to 50 %, even when two or more antidepressants have already failed. A medication that can reduce suicidal thoughts within hours, before any conventional therapy has even begun to take effect.

And yet many people have never seriously heard of it.

Many people hear the name ketamine and immediately think: party drug. Anaesthetic. Addiction risk. These questions are understandable. And they matter. Because this is exactly where the real misunderstanding begins.

Between the operating room and the party basement there is a third space. A medical, therapeutic space. A space in which ketamine does not anaesthetise but can open something. And that is precisely the difference between a crash and healing.

If you want to know straight away whether this is relevant for you At the end of this article you will find a self-check, an overview of indications and contraindications, and the link to book an appointment at Vivecura.

Special focus at Vivecura: Ketamine-Assisted Therapy & Integration

Ketamine therapy is one of my four core areas of focus, alongside gut reset, mold therapy, and heavy metal detoxification. I do not offer this therapy out of theoretical interest. I have experienced it myself. And that experience has not only changed my practice, it has changed my life.

Current area Off-label, medically supervised Integration in focus
My honest framing, before you read on

Behavioural therapy is like walking. Psychoanalysis is like riding a bicycle. Ketamine-assisted therapy with real integration is like driving a Ferrari, you don't just reach the destination, you experience the journey so differently that your inner orientation is changed forever.

All of these modes have their place. Sometimes walking is exactly the right thing. But sometimes a person doesn't need more steps, they need a different quality of experience. That is what I see again and again with ketamine: not a shortcut, but a dimension that other forms of therapy lack.

I come from Syria. And Germany was not a home for me for a long time.

I am grateful to this country, I have to say that here, without qualification. Germany gave me safety when my homeland could no longer do so. It allowed me to study medicine, build a practice, and lead a good life despite all the difficulties. I will never forget that.

And yet: I did not feel at home here for a long time. Safe, yes. Welcomed, yes. But that deep, quiet sense of "this is where I belong" was missing. For years. I kept thinking: maybe I will leave one day. Maybe this isn't permanently mine.

"Where is your home?" That question haunted me. And no thought, no analysis, no conversation truly answered it.

In one of my ketamine sessions, which I had begun without any therapeutic agenda, simply to understand what I was really offering my patients, I experienced something that I can still hardly put into words today. It was not a thought. It was a physical, emotional, visual experience of what home really means.

Home is not a place. Home is a feeling on the inside that I can cultivate, regardless of where I happen to live.

After that session I no longer wanted to leave. Not because Germany had changed. But because I had changed. I stopped expecting from an outer place what can only arise within. I began to experience my practice in Berlin as a conscious decision, not as a temporary stop. I stayed. Not because I had to. But because I wanted to.

The second theme: knowing and changing are two different things.

I was in psychoanalysis. Intensively. Well. I came to understand a lot about myself, my patterns, my relational dynamics, the structures that kept repeating themselves in my romantic relationship at the time. I saw what was not working. I knew the causes. I understood my pattern, intellectually, completely.

And yet nothing essential changed. Not really. My head knew. The rest of me did not.

I knew my pattern. I could name it, explain it, trace it back to childhood. And I went on living it anyway. Knowing and changing are two completely different things.

In the ketamine sessions something different happened. I no longer experienced my patterns as abstract concepts, I saw them. As inner images. As scenes unfolding in front of me. I felt what these patterns had done to me, how they had come into being, what they had once tried to protect. Not cognitively. Holistically. Feeling, understanding, and wanting to change all at once, in a single moment.

That was what had been missing. Not more analysis. Not more knowledge. The experiencing. The difference between reading a map and actually walking the path.

After that experience, change was no longer effortful. It happened almost on its own. Not because ketamine had "healed" me, but because for the first time I had truly felt what I had previously only thought. And once you have experienced it, change becomes effortless.

Classical therapy

Understanding what is happening

Psychoanalysis and behavioural therapy create awareness, cognitive structures, new frames of meaning. You understand the pattern. You know how it came about. You can name it.

Between understanding and lasting change there is often a gap that more understanding cannot close. The head knows. The rest does not.

Ketamine-assisted therapy

Experiencing what is happening

Ketamine opens a state in which old patterns are not only analysed but felt, through inner images, bodily sensations, and emotional truths.

Feeling + understanding + wanting to change arise simultaneously, as a holistic experience. After that, change is no longer an act of willpower. It happens.

1. What ketamine is, and what it is not

Ketamine was developed as an anaesthetic in the early 1960s and is still used worldwide today. In emergency departments, in surgery, in pain medicine. It is one of the few substances that does not depress respiration, stabilises circulation, can be dosed extremely reliably, and has hardly any toxic side effects when used correctly.

Then something fascinating was discovered. At a much lower dose, called subanaesthetic, ketamine can produce an almost opposite effect in depression, trauma, and chronic tension. Not numbing. But opening.

And it is precisely this discovery that has turned psychiatric research on its head over the last twenty years.

Anonymous. 41 years old. Architect from Berlin-Mitte. He came to me after years. Three different antidepressants. Two inpatient stays. Years of psychotherapy. "I no longer feel depressed," he said in our first conversation. "I don't feel anything anymore." That was the worst part. That leaden indifference, that nothingness. We talked about ketamine. Not as a first step, but after a thorough screening and a long conversation about expectations, risks, and goals. After the second infusion he told me: "For the first time in years there was something there again. I don't know how to describe it. But it was there." This is not a miracle. But it is a beginning. And sometimes that beginning is what you need.

2. What happens in the brain, the neurobiology in plain words

Classical antidepressants work on the serotonin or noradrenaline system. That is important and effective. But it takes weeks, sometimes months. And it does not help everyone.

Ketamine takes a different route.

The NMDA receptor: the gateway to change

Ketamine blocks a particular type of receptor in the brain: the NMDA receptor, a glutamate receptor. Glutamate is the brain's most important excitatory neurotransmitter. Imagine NMDA receptors as gates that regulate the flow of information between nerve cells. In chronic depression these gates may be permanently stuck in an unhealthy pattern.

When ketamine blocks these receptors, something surprising happens at first: nerve cells are briefly released from a particular form of inhibition. This leads to a short-term rise in glutamate in other regions. And this glutamate surge activates a cascade that intervenes directly in the cell's architecture.

BDNF, mTOR and synaptogenesis: the actual healing process

Imagine BDNF, brain-derived neurotrophic factor, as the brain's fertiliser. Chronic stress and depression reduce BDNF, the connections between nerve cells become weaker, thinner, fewer.

Ketamine very rapidly triggers an increase in BDNF synthesis. This happens via activation of the mTOR signalling pathway, a kind of cellular hub for growth signals. The result: new synaptic connections form, damaged ones are repaired. This process, which neuroscientists call synaptogenesis, was described by Krystal and colleagues in 2024 in Neuropsychopharmacology, and is responsible for both the rapid and the longer-lasting effects of ketamine.

Mechanism review 2024

Krystal JH, Kavalali ET, and Monteggia LM published a comprehensive review in Neuropsychopharmacology in 2024. Core finding: ketamine's NMDA blockade inhibits eEF2 kinase, which lifts the suppression of BDNF translation. BDNF activates TrkB receptors, leading to rapid synaptic plasticity. At the same time, AMPA receptor stimulation activates the mTOR signalling pathway and promotes synaptogenesis, accounting for both the rapid and the sustained effects.

Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. 2024;49(1):41–50.

What does this mean for the person? Metaphorically speaking, in depression the brain receives fewer growth signals. Connections that stand for joy, hope, motivation become weaker. Ketamine can set this process in motion within hours, and biologically that is unique among the known antidepressants.

Reframe

Ketamine is not a happiness hormone. It is a growth impulse. It does not make you "happy." For a certain period of time, it creates the neurobiological conditions under which change becomes possible. What then happens within that window is decided in the therapeutic context, in the integration, in the conversation afterwards. That is the difference between an experience and a healing.

3. How quickly does ketamine work, and how long does it last?

This is perhaps the most fascinating part.

Classical antidepressants need six to eight weeks. Ketamine begins to work within hours. The peak of the antidepressant effect is reached 24 to 72 hours after an infusion.

This is not mysticism. These are the synaptic growth processes that begin immediately after the infusion.

Single infusion vs. course of treatment

A single infusion (0.5 mg/kg over 40 minutes) lasts up to seven days in many people. That is meaningful, but not enough for sustained change. Repeated infusions over two to three weeks can prolong the effect, although the optimal number and frequency are still under research.

Real-world meta-analysis

In 2022, Alnefeesi and colleagues analysed 79 real-world studies with a total of 2,665 patients with treatment-resistant depression in one of the most comprehensive reviews to date. The result: on average, about 45 % of patients showed a response (≥50 % symptom reduction), and about 30 % achieved remission. Important: the effect size was substantial (Hedges g = 1.44), and the effect did not diminish with repeated treatment.

Alnefeesi Y et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693–709.
An honest reading of the numbers

In the original article, response rates of 50–80 % were quoted. That is true for some controlled single studies under optimal conditions. The summary real-world evidence shows somewhat lower numbers: about 45 % response, 30 % remission. That is still extraordinarily good for a patient group that has not responded to anything else. But it is important to be honest about it: ketamine does not help everyone. And it does not cure. It can open a therapeutic space.

4. Treatment-resistant depression: when nothing else works

I bet you know the feeling. Or know someone who does.

Not sick enough to need hospital. But not well enough to really live. A life in grey. Medications that do nothing. Conversations that go in circles. That exhausted "I have already tried everything."

Treatment-resistant depression is defined as a lack of improvement despite at least two adequate antidepressant treatments in the current depressive episode. It affects an estimated one in three people with severe depression.

Overview of overviews 2024

In 2024, Rodolico and colleagues published an overview in Frontiers in Psychiatry covering 26 systematic reviews and 44 randomised trials with more than 3,000 patients. The central finding: ketamine and its S-enantiomer esketamine consistently show a rapid, significant antidepressant effect in treatment-resistant depression. The authors explicitly emphasise, however: the overall study quality is low to moderate, and long-term effects have not been sufficiently researched. That matters. The evidence is real, but it is not infallible.

Rodolico A et al. Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis. Front Psychiatry. 2024;15:1325399.

What does this mean in practice? In treatment-resistant depression, ketamine can bring noticeable relief within hours. It is not a magic bullet. But in the research it is by far the fastest and most powerful instrument we have for people for whom everything else has failed.

And what about suicidality?

This is a particularly important point. Classical antidepressants take weeks to develop their anti-suicidal effects, and during the first two weeks the suicide risk can briefly even increase. Ketamine can reduce suicidal thoughts within hours, sometimes after just a single infusion. Clinically, this can be life-saving.

5. Bipolar depression: when the dark phases will not lift

People with bipolar disorder know a particular dilemma: many medications help against mania, but barely against the deep depressive phases. And it is precisely in those phases that the greatest risk lies.

Systematic review

In 2021, Bahji, Zarate and Vazquez published a systematic review of ketamine in bipolar depression in the International Journal of Neuropsychopharmacology. They analysed 6 studies with a total of 135 patients. Participants received ketamine infusions (0.5 mg/kg) in addition to a mood stabiliser. In most studies the depressive phase improved rapidly. The risk of a manic switch was low, but present. The authors describe this as preliminary evidence that requires further research.

Bahji A, Zarate CA, Vazquez GH. Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol. 2021;24(7):535–541.
Important caveat: In bipolar disorder, ketamine is not a first-line treatment and should only be used with close psychiatric supervision and in combination with a mood stabiliser. The risk of a manic switch is small but real. Ketamine does not replace mood-stabilising medication.

6. PTSD: when the trauma keeps living in the nervous system

Post-traumatic stress disorder develops after extreme experiences. Violence, loss, accidents, emotional neglect. The symptoms are wearing: flashbacks, nightmares, dissociation, constant hyperarousal, the feeling of being cut off from yourself or the world.

What may make ketamine particularly relevant here? Traumatic memories are deeply encoded in the nervous system. Classical therapies need time to reach those layers. Ketamine can ease access to emotionally charged content by briefly reducing cognitive control and opening access to inner experience.

First RCT of ketamine in PTSD

Feder and colleagues (2014) published the first randomised, controlled crossover trial of ketamine in chronic PTSD in JAMA Psychiatry. Compared with active placebo (midazolam), a single ketamine infusion produced a significantly greater reduction in PTSD symptoms 24 hours after administration. This was a proof of concept, the first demonstration that ketamine has any effect in PTSD at all.

Feder A et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681–688.
PTSD meta-analysis 2024

Borgogna and colleagues (2024) summarised the available RCTs of ketamine in PTSD in a meta-analysis. Ketamine showed consistent reductions on PTSD symptom scales. The authors emphasise: ketamine works best when it is not used as pure sedation, but as a door-opener in combination with therapeutic guidance and integration.

Borgogna NC et al. So how special is 'special K'? A systematic review and meta-analysis of ketamine for PTSD RCTs. Eur J Psychotraumatol. 2024.
An honest reading, the PTSD evidence is nuanced

An important finding missing from the original article: in 2022 Abdallah and colleagues tested repeated ketamine infusions in PTSD in one of the largest RCTs to date (n=158 veterans). They found significant improvements in depression, but no significant effect on the core PTSD symptoms (PCL-5, CAPS-5). What this means: the evidence for ketamine in PTSD is promising, but not yet consistent. The strongest effects are seen in combination with psychotherapy.

7. Ketamine alone opens a door, therapy turns it into a room

For me this is one of the most important points. And it is often underestimated.

Ketamine alters consciousness. There is a window in which new perspectives can emerge, in which old patterns are less rigid, in which something that has been locked away can become movable again. But that window closes.

What you do inside that window is what makes the difference. That is the heart of ketamine-assisted psychotherapy.

Systematic review KAP 2022

Drozdz and colleagues published a systematic narrative review of the literature on ketamine-assisted psychotherapy in 2022 in the Journal of Pain Research. They showed that combining ketamine with psychotherapeutic elements before, during and after the session consistently produces more stable and longer-lasting effects than ketamine alone. This holds true for depression, PTSD, and addiction disorders.

Drozdz SJ et al. Ketamine assisted psychotherapy: a systematic narrative review of the literature. J Pain Res. 2022;15:1691–1706.
Convergence study 2025

In 2025, Sakopoulos and Todman describe in the International Journal of Molecular Sciences the mechanism by which psychotherapy prolongs the effect of ketamine: the neuroplastic state after ketamine administration creates an "open phase" of heightened synaptic malleability. Psychotherapeutic interventions during this window can anchor new cognitive and emotional patterns more deeply than they could without this biological precondition.

Sakopoulos S, Todman M. The effects of psychotherapy on single and repeated ketamine infusion(s) therapy for TRD. Int J Mol Sci. 2025;26(14):6673.

Ketamine alone is like a door that opens briefly. Without integration, you walk past it. With guidance it becomes a room you can actually enter.

8. What you experience in a session

Every experience is unique. But there are recurring patterns that most people describe.

Dissociation

A sense of being an observer. You perceive yourself as if you were slightly outside of yourself. This can be liberating if you usually feel very stuck inside your own head.

Old emotions

Things that long had no place are allowed to surface. Sometimes tears. Sometimes anger. Sometimes simply a deep exhaustion that finally has room to be there.

Inner images

Many people describe visual or symbolic experiences. Not hallucinations in the strict sense, more like intense dreaming with full awareness.

Bodily sensations

Warmth, tingling, a sense of softness or heaviness. Many experience a deep state of bodily relaxation that feels very unfamiliar.

Many people experience this as shaking and clarifying. Sometimes something rises up that has had no place for years. That can be overwhelming. But this is exactly the point of a safe therapeutic frame: not to suppress. But to say: you are allowed to be here.

9. Is ketamine addictive? An honest answer

I hear this question in every initial consultation. And it is a fair one.

Ketamine is misused recreationally, often in very high doses, daily, combined with other substances. That carries real risks: psychological dependence, bladder damage (so-called ketamine cystitis), memory impairment with chronic use.

But that is a completely different setting from therapeutic use.

Risk assessment recreational vs. medical use

Morgan and Curran (2012, Addiction) showed that the negative effects of ketamine depend strongly on dose, frequency, and context. Frequent recreational use is associated with an increased risk of dependence, cognitive impairments, and bladder damage. The authors classify ketamine as a substance with low to moderate physical dependence potential, considerably lower than that of alcohol, opioids, or benzodiazepines.

Morgan CJA, Curran HV. Ketamine use: a review. Addiction. 2012;107(1):27–38.

In therapeutic use, fundamentally different parameters apply: precisely dosed individual administrations with long intervals between them, under medical supervision, with psychological preparation and integration. Ketamine does not produce a physical withdrawal syndrome the way alcohol, benzodiazepines, or opioids do.

However: psychological dependence can develop if people use ketamine to escape feelings, without therapeutic guidance. The opposite of the therapeutic goal. That is why the framework is decisive. The point is not to create a new attachment. The point is to become freer.

Reframe

Ketamine cystitis is real, but not relevant in therapeutic use. Bladder damage develops with daily use of high doses over months. That has nothing to do with the therapeutic protocol. An infusion every few weeks under medical supervision does not carry that risk. Even so, monitoring is appropriate with repeated treatments.

10. Mechanism of action and clinical practice: what the neurobiology means for the experience

I want to go one step further. Because the neurobiology explains something that many patients describe intuitively but find hard to put into words.

In severe depression or chronic trauma, synaptic connections literally shrink. Not metaphorically. Microscopically measurable. The prefrontal cortex, which is responsible for perspective, planning, and emotional regulation, loses connection density.

What ketamine sets in motion is, at its core, a process of regeneration. New synaptic connections form within hours. This state of heightened neuronal plasticity, which lasts for a certain period after the infusion, is the biological window in which therapeutic work can reach more deeply.

Many patients describe it like this: "My head was finally still. And for the first time in years I could feel what was really there."

That is not suggestion. That is synaptogenesis.

11. How a treatment with me unfolds

Every person brings a unique story, a different nervous system, and an individual body. That is why no treatment with me starts with an infusion. It starts with real listening.

Step 1: History-taking and holistic diagnostics

We begin with an in-depth conversation about your life, your symptoms, previous therapies, and inner themes. That also includes physical diagnostics, because emotional state and biochemical foundation are inseparable.

What I look at

  • Nutrients: vitamin D, B12, omega-3, magnesium, zinc
  • Hormones and thyroid: including fT3, fT4, anti-TPO
  • Gut flora and inflammatory markers: hsCRP, microbiome status
  • Stress system: cortisol diurnal profile, HRV, sleep profile
  • Environmental toxins: when indicated by history (mold, heavy metals)
  • Cardiovascular: particularly relevant before ketamine administration (blood pressure monitoring)

Step 2: Preparation and setting conversation

Before you receive ketamine, we clarify: what is your goal? What is allowed to come up? What will you need if it becomes intense? This conversation is decisive. It gives your experience a safe frame.

Step 3: The infusion, precisely dosed, medically monitored

0.5 mg/kg of ketamine slowly intravenously over about 40 minutes. Heart rate and blood pressure are continuously monitored. An eye mask reduces external stimuli. Music supports the emotional process. I am present the entire time.

The setting makes the difference. Ketamine can do more when the space is set up correctly for it.

Step 4: Integration

After every session we talk: what did you experience? What feelings were there? What has changed? The experience is the impulse. The integration turns it into change.

Step 5: Course and conclusion

After several sessions (depending on the situation, typically 4–6) a new inner space often emerges: more clarity, more access to feelings, more self-direction. My goal is not for you to stay with me. My goal is for you to learn how to accompany yourself.

12. Why I always work holistically

Many people, when they think of mental health, only think of conversations, diagnoses, and medications. But what about a vitamin D deficiency that blocks drive and mood? A chronic inflammation that weighs on the body and the nervous system? A dysbiosis in the gut that, via the gut-brain axis, dulls emotional life?

Your emotional state has biochemical foundations. Ketamine does not treat isolated symptoms. It is part of a holistic approach that takes every level into account.

Reframe: ketamine is not a shortcut

Ketamine does not replace diagnostic work, sleep, the way you live in your relationships, or a foundation of nutrition and movement. It is a tool within a systemic approach. Anyone who sees ketamine as a shortcut misses the essential point: the window that ketamine opens can only really be used if the rest of the system is working with it.

13. Who ketamine is suitable for, and who it is not

Possibly suitable Treatment-resistant depression (at least 2 antidepressants without sufficient effect). PTSD where classical forms of therapy are not enough. Bipolar depression under psychiatric supervision with a mood stabiliser. People who don't just want to talk, but to experience and integrate.
Contraindications / not yet suitable Untreated or active psychosis. Active mania. Uncontrolled high blood pressure or severe heart disease. Active addiction without accompanying treatment. Pregnancy. Lack of willingness to prepare and integrate.
Approval status: Esketamine (as a nasal spray, Spravato) has been approved in the EU since December 2019 for treatment-resistant depression, and since February 2021 also for acute depressive episodes that constitute a psychiatric emergency. Intravenous racemic ketamine remains off-label in Germany for psychiatric indications, meaning it is used without formal approval for this purpose, under individual medical responsibility. This is legal and clinically established, but it requires transparency with patients.

Ketamine is not only for severe diagnoses.

If you have read this far, you have learned a lot about treatment-resistant depression, PTSD, and bipolar conditions. That is the scientific language in which ketamine is researched and described. But I want to be honest: that is not the full picture of what I see in my practice.

Many of the people who come to me have none of these severe diagnoses. No treatment-resistance, no clinical condition listed in a DSM catalogue. And yet they have benefited deeply from ketamine.

My personal conviction

I believe that ketamine-assisted therapy with real integration can support anyone who wishes to expand their consciousness, deliberately quiet their thinking mind, and heal more through feeling and experiencing. This is not an exception to the medical benefit. It is the very heart of it.

We live in a culture that places cognitive understanding above bodily experience. We analyse, name, categorise. We know a lot about ourselves. And yet often little changes. Not because we know too little, but because knowledge alone is not enough. The key lies in the experiencing, not in the understanding.

Ketamine can temporarily quiet the analytical part of the mind, the part that is constantly evaluating, controlling, and commenting. What remains is a deeper access to what is really going on inside us. Images, feelings, connections that do not appear in ordinary states of consciousness. This is not a mystical process. It is neurobiology: less filter, more access.

People with no clinical diagnosis who simply felt that they were not quite themselves. Who understood why they had certain patterns but could not let go of them. Who had already come a long way in therapy and yet had the feeling that one layer was still missing.

These people often left the ketamine sessions different from how they came in. Not because something that was sick had been "healed". But because something that had been separated was integrated. More contact with themselves. More clarity. Less inner noise.

So please don't let the clinical language of this article put you off. If you feel that you are reaching the limits of pure thinking, that you want to feel more and analyse less, or that you are looking for a deep experience that can spark real change from within, that is a fully valid reason for a conversation. You don't have to be sick to benefit from ketamine. You only have to be willing.

14. Self-check: could ketamine be relevant for you?

Block 1: Your treatment history

  • Have you tried at least two different antidepressants in adequate dose and duration without significant improvement?
  • Are you in psychotherapy, or have you been, and notice that you are "going in circles" or not really getting through?
  • Do you feel that you know what your problem is, but cannot get emotional access to it?
  • Do you have a PTSD diagnosis, and have classical trauma therapies helped little so far?

Block 2: Your inner readiness

  • Are you ready to engage with a deeper, possibly intense inner experience?
  • Can you imagine seriously working with what comes up after a session?
  • Do you have a fundamental interest in what is going on inside you, beyond the symptom?
  • Are you free of active addiction risk and not in an acute psychotic phase?

Please seek prompt medical evaluation if:

  • Acute suicidality, ketamine can be part of the solution but not a substitute for emergency care
  • An unclear diagnosis, before ketamine is considered, the underlying diagnosis must be in place
  • Known heart conditions or uncontrolled high blood pressure
  • Active psychosis or known schizophrenia
  • Wanting to conceive, or pregnancy

Ketamine in the system, the connection to my other specialty areas

Mental health is rarely an isolated matter. In my practice I regularly see: people struggling with treatment-resistant depression or PTSD often carry a biological burden at the same time, mold toxins that produce neuroinflammation, heavy metals that disrupt neurotransmitter synthesis, or a dysbiotic gut microbiome that destabilises mood through the gut-brain axis. Ketamine opens a window. But that window is most useful when the entire system is working with it.

Ketamine

Neuroplasticity, therapeutic window, integration

this area
Gut Reset

90 % of serotonin is produced in the gut. Dysbiosis directly limits therapeutic success.

Mold

Mycotoxins generate neuroinflammation and block the healing processes that ketamine is meant to set in motion.

Heavy Metals

Mercury and lead disrupt neurotransmitter enzymes. Reduce the toxin load, and the window becomes larger.

Ready for an initial conversation?

No pressure. No prior decision. Just an honest conversation about what has been tried so far, what has been missing, and whether ketamine could be the next sensible step.

Book an appointment at Vivecura

Sources

  1. Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. 2024;49(1):41–50. DOI: 10.1038/s41386-023-01629-w
  2. Li N, Lee B, Liu RJ et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964. DOI: 10.1126/science.1190287
  3. Rodolico A et al. Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis. Front Psychiatry. 2024;15:1325399. DOI: 10.3389/fpsyt.2024.1325399
  4. Alnefeesi Y et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693–709.
  5. Nikolin S et al. Ketamine for the treatment of major depression: a systematic review and meta-analysis. eClinicalMedicine. 2023. ScienceDirect.
  6. Shiroma PR et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry. 2020;10:206. DOI: 10.1038/s41398-020-00897-0
  7. Bahji A, Zarate CA, Vazquez GH. Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol. 2021;24(7):535–541. DOI: 10.1093/ijnp/pyab023
  8. Feder A et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681–688. DOI: 10.1001/jamapsychiatry.2014.62
  9. Feder A et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021;178(2):193–202. DOI: 10.1176/appi.ajp.2020.20050596
  10. Abdallah CG et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of PTSD in veterans. Neuropsychopharmacology. 2022;47(8):1574–1581.
  11. Borgogna NC et al. So how special is 'special K'? A systematic review and meta-analysis of ketamine for PTSD RCTs. Eur J Psychotraumatol. 2024.
  12. Almeida K et al. Effectiveness of ketamine for the treatment of PTSD in real world settings. 2024.
  13. Drozdz SJ et al. Ketamine assisted psychotherapy: a systematic narrative review of the literature. J Pain Res. 2022;15:1691–1706. DOI: 10.2147/JPR.S360733
  14. Sakopoulos S, Todman M. The effects of psychotherapy on single and repeated ketamine infusion(s) therapy for TRD. Int J Mol Sci. 2025;26(14):6673. DOI: 10.3390/ijms26146673
  15. Morgan CJA, Curran HV. Ketamine use: a review. Addiction. 2012;107(1):27–38. DOI: 10.1111/j.1360-0443.2011.03576.x
  16. Schak KM et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016;173(3):215–218.
  17. Singh JB et al. Approval of esketamine for treatment-resistant depression. Lancet Psychiatry. 2020;7(3):232–235. DOI: 10.1016/S2215-0366(19)30533-4
  18. EMA. Spravato (esketamine): EU marketing authorisation December 2019, extended February 2021. European Medicines Agency.
  19. Anand A et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388(25):2315–2325. DOI: 10.1056/NEJMoa2302399
  20. Guo X et al. Comparative safety and tolerability of ketamine for treatment-resistant depression: a meta-analysis. Front Pharmacol. 2025. DOI: 10.3389/fphar.2025.1681060